# Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease

> **NCT00200525** · PHASE3 · COMPLETED · sponsor: **Mylan Bertek Pharmaceuticals** · enrollment: 60 (—)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** apomorphine HCl injection

## Key facts

- **NCT ID:** NCT00200525
- **Lead sponsor:** Mylan Bertek Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** —
- **Final completion:** 2002-06
- **Target enrollment:** 60 (—)
- **Last updated:** 2005-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00200525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00200525, "Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00200525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*